Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma

Cancer

Volumn 119, Issue 24, 2013, Pages 4259-4267

  Chen, Ya Wei ^a,b   Kao, Shou Yen ^a   Wang, Hsiao Jung ^b   Yang, Muh Hwa ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

histone modification; oral squamous cell carcinoma; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE H3; LYSINE;

ABLATION THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EMBEDDING; FEMALE; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; ORAL SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME; TUMOR INVASION;

HISTONE MODIFICATION; ORAL SQUAMOUS CELL CARCINOMA; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HISTONES; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84889887246     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28356     Document Type: Article

References (33)

1. Chen YW, Chen CY, Chiang SC, Lui MT, Kao SY, Yang MH,. Predictors and impact of microsurgical complications in patients with locally advanced oral squamous cell carcinoma. Cancer Sci. 2012; 103: 1672-1678.
2. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415-428.
3. Mascolo M, Siano M, Ilardi G, et al. Epigenetic disregulation in oral cancer. Int J Mol Sci. 2012; 13: 2331-2353.
4. Kyrgidis A, Tzellos TG, Triaridis S,. Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog. 2010; 9: 3.
5. Hake SB, Xiao A, Allis CD,. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer. 2004; 90: 761-769.
6. Esteller M,. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007; 8: 286-298.
7. Kurdistani SK,. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer. 2007; 97: 1-5.
8. Strahl BD, Allis CD,. The language of covalent histone modifications. Nature. 2000; 403: 41-45.
9. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009; 174: 1619-1628.
10. Kurdistani SK,. Histone modifications in cancer biology and prognosis. Prog Drug Res. 2011; 67: 91-106.
11. Chen YW, Kao SY, Yang MH,. Analysis of p16(INK4A) expression of oral squamous cell carcinomas in Taiwan: prognostic correlation without relevance to betel quid consumption. J Surg Oncol. 2012; 106: 149-154.
12. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005; 435: 1262-1266.
13. Ellinger J, Kahl P, von der Gathen J, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate. 2010; 70: 61-69.
14. Ellinger J, Kahl P, von der Gathen J, et al. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest. 2012; 30: 92-97.
15. Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009; 69: 3802-3809.
16. Leszinski G, Gezer U, Siegele B, Stoetzer O, Holdenrieder S,. Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res. 2012; 32: 2199-2205.
17. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol. 2007; 25: 4358-4364.
18. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res. 2008; 14: 7237-7245.
19. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ,. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol. 2008; 15: 1968-1976.
20. Tzao C, Tung HJ, Jin JS, et al. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol. 2009; 22: 252-260.
21. I H, Ko E, Kim Y, et al. Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 2010; 19: 566-573.
22. Ellinger J, Kahl P, Mertens C, et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer. 2010; 127: 2360-2366.
23. Rogenhofer S, Kahl P, Mertens C, et al. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int. 2012; 109: 459-465.
24. Rogenhofer S, Kahl P, Holzapfel S, Von Ruecker A, Mueller SC, Ellinger J,. Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res. 2012; 32: 879-886.
25. Mosashvilli D, Kahl P, Mertens C, et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 2010; 101: 2664-2669.
26. He C, Xu J, Zhang J, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012; 43: 1425-1435.
27. Cai MY, Hou JH, Rao HL, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011; 17: 12-20.
28. Agger K, Cloos PA, Rudkjaer L, et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009; 23: 1171-1176.
29. Yao JY, Zhang L, Zhang X, et al. H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. J Biol Chem. 2010; 285: 18828-18837.
30. Abbosh PH, Montgomery JS, Starkey JA, et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 2006; 66: 5582-5591.
31. Beumer JH, Tawbi H,. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol. 2010; 5: 196-208.
32. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6: 38-51.
33. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007; 13: 2318-2322.